Abstract 2078
Background
Fight-202 is a phase 2 study (NCT02924376) of pemigatinib (INCB054828), a selective, potent, oral inhibitor of FGFR1, 2, and 3 in pts with advanced CCA. Interim results from the first 47 FGFR2+ CCA pts with ≥8 months (mo) of follow-up demonstrated an objective response rate (ORR) of 40.4%, disease control rate (DCR) of 85%, median progression-free survival (mPFS) of 9.2 mo, and median overall survival (mOS) of 15.8 mo, based on independent central review. Here we report the frequency of FGFR2 rearrangement partners and co-occurring alterations and their impact on clinical outcomes.
Methods
Comprehensive genomic profiling was performed in all pts prescreened and/or enrolled in fight-202 using FoundationOne. Clinical data were reported previously.
Results
Among 118 FGFR2+ pts identified, 54 unique FGFR2 rearrangement partners were observed, of which 74.1% (n = 40) were unique to a single patient. BICC1 was the most frequent FGFR2 rearrangement partner (29.7% [n = 35]). FGFR2+ pts had fewer genomic alterations (3.36 alterations/pt) than unaltered pts (4.6 alterations/pt). The most frequently co-altered gene, BAP1, was altered in 39.8% (n = 47) of FGFR2+ pts. As of the data cutoff date (July 24, 2018), 47 FGFR2+ pts were treated with pemigatinib and followed for ≥8 mo. There were no meaningful differences in ORR (42.9% vs 39.4%), mPFS (8.9 mo vs 9.6 mo), or mOS (not reached [NR] vs 15.8 mo) in patients with FGFR2-BICC1 (n = 14) versus other FGFR2 rearrangements. Similarly, no meaningful difference in ORR (53.3% vs 34.4%), mPFS (8.9 mo vs NR), or mOS (NR vs 15.8 mo) was observed in pts with BAP1 loss-of-function mutations (n = 15). Among other co-occurring genomic alterations, pts with TP53 alterations (n = 5) had no objective responses (0% vs 45.2%) and shorter mPFS (6.2 mo vs NR) and mOS (10.5 mo vs NR).
Conclusions
Despite myriad FGFR2 rearrangement partners identified in the study, an interim analysis did not indicate a difference in ORR, mPFS, or mOS between the most common rearrangement partner (BICC1) and other partner genes. Alterations in TP53, but not BAP1, were associated with decreased clinical benefit.
Clinical trial identification
Editorial acknowledgement
Simon J. Slater, PhD, CMPP, of Envision Pharma Group (Philadelphia, PA), funded by Incyte Corporation.
Legal entity responsible for the study
Incyte Corporation.
Funding
Incyte Corporation.
Disclosure
A. Hollebecque: Consulting/Advisory Role, Travel/Accommodation/Expenses, Courses/Trainings: Amgen; Consulting/Advisory Role: Spectrum Pharmaceuticals; Consulting/Advisory Role, Travel/Accommodation/Expenses: Lilly; Consulting/Advisory Role, Travel/Accommodation/Expenses: Debiopharm; Travel/Accommodation/Expenses: Servier; Travel/Accommodation/Expenses: Incyte; Courses/Trainings: Bayer; Courses/Trainings: Eisai; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Janssen Cilag; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Sanofi. I.M. Silverman: Shareholder / Stockholder / Stock options, Full / Part-time employment: ): Incyte Research Institute, Incyte Corporation. S. Owens: Shareholder / Stockholder / Stock options, Full / Part-time employment: ): Incyte Research Institute, Incyte Corporation. L. Féliz: Shareholder / Stockholder / Stock options, Full / Part-time employment: Incyte Corporation. C.F. Lihou: Shareholder / Stockholder / Stock options, Full / Part-time employment: Incyte Corporation. H. Zhen: Shareholder / Stockholder / Stock options, Full / Part-time employment: Incyte Corporation. R.C. Newton: Shareholder / Stockholder / Stock options, Full / Part-time employment: ): Incyte Research Institute, Incyte Corporation. T.C. Burn: Shareholder / Stockholder / Stock options, Full / Part-time employment: ): Incyte Research Institute, Incyte Corporation. D. Melisi: Research Grants (Institution), Advisory/Consultancy Role: Shire; Research Grants (Institution), Advisory/Consultancy Role: Incyte; Research Grants (Institution), Advisory/Consultancy Role: Evotec; Research Grants (Institution): Celgene; Advisory/Consultancy Role: Eli Lilly; Advisory/Consultancy: Baxter. All other authors have declared no conflicts of interest.
Resources from the same session
5747 - The routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified
Presenter: Fanny Preat
Session: Poster Display session 2
Resources:
Abstract
1837 - Oncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer
Presenter: Kenjiro Jimbo
Session: Poster Display session 2
Resources:
Abstract
4347 - Pneumonitis and fibrosis after breast cancer radiation.
Presenter: Jarle Karlsen
Session: Poster Display session 2
Resources:
Abstract
2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society
Presenter: Sungmin Park
Session: Poster Display session 2
Resources:
Abstract
804 - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer
Presenter: Chang-ik Yoon
Session: Poster Display session 2
Resources:
Abstract
2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe
Presenter: Francesco Giusti
Session: Poster Display session 2
Resources:
Abstract
1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium
Presenter: Didier Verhoeven
Session: Poster Display session 2
Resources:
Abstract
1534 - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: Poster Display session 2
Resources:
Abstract
4363 - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
Presenter: Emilia Montagna
Session: Poster Display session 2
Resources:
Abstract
2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study
Presenter: Idlir Licaj
Session: Poster Display session 2
Resources:
Abstract